Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

June 7, 2026 - 23:29

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is drawing renewed attention from Wall Street as a penny stock worth watching. On May 8, analysts at Stifel reiterated a Hold rating on the stock but raised their price target to $4 from $3. That increase signals growing confidence in the company's pipeline and its broader strategy.

The revised target reflects Stifel's optimism about Aclaris's multi-targeting approach, which the firm believes could unlock value in the biotech space. While penny stocks carry higher risk, Aclaris has managed to stay on the radar of institutional investors looking for speculative plays with potential catalysts.

Aclaris focuses on developing treatments for immuno-inflammatory diseases. Its lead programs target pathways that could address conditions with limited current options. The company has been working to advance its clinical trials and build momentum around its science.

For investors willing to take on volatility, Aclaris offers a mix of risk and reward. The Stifel upgrade suggests that the firm sees enough progress to justify a higher valuation, even if it is not yet ready to issue a full Buy. The stock remains a name to track for those following small-cap biotech plays.